Issues relating to staffing, stock monitoring, inventory procedures, stronger audit mechanisms and better organisation of pharmacy premises are highlighted in Audit Report 1/2026 by the Court of Audit on EOPYY pharmacies. The report covers 2024 and 2025 (to 30 April 2025).
It also notes that EOPYY pharmacies handle mainly high-cost medicines, which are essential to promoting individual and public health—constitutional goods closely bound up with the core of human dignity. It says the thematic audit found no evidence of mismanagement of pharmaceutical stock in the form of deliberate removal or damage caused by negligence to stock held in EOPYY pharmacy warehouses.
In 2025, EOPYY pharmacies served about 328,500 unique patients, averaging around 150,000 patients a month, and filled 2.41 million prescriptions. This particularly demanding workload was handled by 160 pharmacists.
Corrective measures by EOPYY
EOPYY reaffirms its commitment to continually improving the operation of its pharmacies. In response to the Court of Audit’s findings, EOPYY says it has already taken the following measures:
– Organisational improvements: EOPYY’s board approved a draft Presidential Decree on the organisation, which has been submitted for further action.
– Digital transformation: The new management system for EOPYY pharmacies is already operating in 30 of the organisation’s pharmacies. It includes detailed records of medicine batch numbers and expiry dates, improving traceability and stock monitoring.
– Stronger checks: Strengthening internal controls, improving oversight and clearly allocating responsibilities are priorities.
– Pharmacy premises: Work is under way to upgrade EOPYY pharmacy premises, either through renovations or relocations.
“EOPYY’s aim is to ensure the safe and rational management of high-cost medicines, the effective use of public resources and uninterrupted service for insured people,” the organisation said in a statement.